Adults with severe asthma who had poor inhaled corticosteroid/long-acting beta agonist adherence in their first year of tezepelumab did not differ from those with better adherence in several clinical outcomes, according to study data.
These findings were published in The Journal of Allergy and Clinical Immunology: In Practice.
“This supports the notion that for some patients, the extent of [type 2] inhibition offered by tezepelumab may be sufficient to make the anti-inflammatory effect of ICS appear redundant,” Grainne d’Ancona, MSc, consultant pharmacist at Guy’s and St. Thomas’ NHS Foundation

Patients with solid tumors, such as breast and gastrointestinal cancers, who also have clonal hematopoiesis of indeterminate potential could have a significantly higher risk for cardiovascular disease.
A retrospective analysis of more than 8,000 individuals with solid malignancies showed those who had clonal hematopoiesis of indeterminate potential (CHIP) had a 26% higher risk for heart failure, and those who received extensive chemotherapy had the greatest risk.
“Being able to use CHIP in this way, to help give patients more precise chemotherapy, that was pretty exciting and surprising,”

LAS VEGAS — GLP-1 receptor agonists offer more than weight loss for patients with inflammatory bowel disease, with markedly improved outcomes indicating anti-inflammatory benefit, according to data presented at Crohn’s & Colitis Congress.
Researchers found that corticosteroid use, hospitalization, intestinal resection and mortality were significantly lower among patients with IBD who were treated with GLP-1s compared with a control group of patients with IBD who were not. However, ED visits were similar between the ulcerative colitis GLP-1 group and control group; ED visit results differed